This rodent study suggests that activating serotonin 2A receptors is essential for tryptamine-based psychedelics to produce antidepressant-like effects in rodents. The study also suggests that psychedelic tryptamines can induce hallucinogenic and therapeutic effects through activation of the same receptor. It highlights the need for full mechanistic understanding of how these molecules produce therapeutic effects.
Psychedelic compounds have displayed antidepressant potential in both humans and rodents. Despite their promise, psychedelics can induce undesired effects that pose safety concerns and limit their clinical scalability. The rational development of optimized psychedelic-related medicines will require a full mechanistic understanding of how these molecules produce therapeutic effects. While the hallucinogenic properties of psychedelics are generally attributed to activation of serotonin 2A receptors (5-HT2ARs), it is currently unclear if these receptors also mediate their antidepressant effects as several nonhallucinogenic analogues of psychedelics with antidepressant-like properties have been developed. Moreover, many psychedelics exhibit promiscuous pharmacology, making it challenging to identify their primary therapeutic target(s). Here, we use a combination of pharmacological and genetic tools to demonstrate that activation of 5-HT2A receptors is essential for tryptamine-based psychedelics to produce antidepressant-like effects in rodents. Our results suggest that psychedelic tryptamines can induce hallucinogenic and therapeutic effects through activation of the same receptor.
Papers cited by this study that are also in Blossom
Olson, J. A. · Neuroscience Insights (2018)
Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)
Inserra, A., De Gregorio, D., Gobbi, G. · Pharmacological Reviews (2021)
Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)
Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)
Carhart-Harris, R. L., Bolstridge, &. M., Day, C. M. J. et al. · Psychopharmacology (2017)
Goodwin, G. M., Aaronson, S. T., Alvarez, O. et al. · New England Journal of Medicine (2022)
Shao, L-X,, Liao, C., Gregg, I. et al. · Neuron (2021)
Griffiths, R. R. · Journal of Psychopharmacology (2008)
Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)
Olson, D. E. · ACS Pharmacology and Translational Science (2020)
Olson, D. E. · Biochemistry (2022)
Kadriu, B., Greenwald, M., Ba et al. · International Journal of Neuropsychopharmacology (2020)
Savalia, N., Shao, L-X,, Kwan, A. C. · Trends in Neuroscience (2021)
Kwan, A. C., Olson, D. E., Preller, K. H. et al. · Nature Medicine (2022)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Holze, F., Vizeli, P., Ley, L. et al. · Neuropsychopharmacology (2020)
Halberstadt, A. L., Chatha, M., Klein, A. K. et al. · Neuropharmacology (2020)
Gonza ´lez-Maeso, J., Weisstaub, N. V., Zhou, M. et al. · Neuron (2007)
Cao, D., Yu, J., Wang, H. et al. · Science (2022)
Serra, Y. A., Barros-Santos, T., Anjos-Santos, A. et al. · Psychopharmacology (2022)
Hesselgrave, N., Troppoli, T. A., Wulff, A. B. et al. · PNAS (2021)
Cameron, L. P., Tombari, R. J., Lu, J. et al. · Nature (2020)
Dong, C., Ly, C., Dunlap, L. E. et al. · Cell (2021)
Kaplan, A. L., Confair, D. N., Kim, K. et al. · Nature (2022)
Shen, H. W., Jiang, X. L., Winter, J. C. et al. · Current Drug Metabolism (2010)
Greb, A. C., Vargas, M. V., Duim, W. C. et al. · ACS Pharmacology and Translational Science (2020)
De La, M., Revenga, F., Zhu, B. et al. · Cell Reports (2021)
Papers in Blossom that reference this study
Avram, M., Menegaux, A., Müller, F. et al. · Cell Reports (2026)
Vargas, M. V., Hatzipantelis, C. J., Dunlap, L. E. et al. · ACS Chemical Neuroscience (2026)
Baker, J. J., Kogan, E., Lu, J. et al. · Biorxiv (2026)
Thuery, G., Crossen, F., Mc Loone, D. et al. · Therapeutic Advances in Psychopharmacology (2026)
Singleton, S. P., Timmermann, C., Luppi, A. I. et al. · Communications Biology (2025)
Lu, O. D., White, K., Raymond, K. et al. · Biorxiv (2025)
Shao, L-X,, Tan, D., Liao, C., Davoudian, P. A. et al. · Nature Communications (2025)
Chisamore, N., Kaczmarek, E. S., Doyle, Z. et al. · Canadian Journal of Psychiatry (2025)
Calder, A. E., Hase, A., Hasler, G. · Molecular Psychiatry (2024)
Fleury, S., Nautiyal, K. M. · Biorxiv (2024)
Warren, A. L., Lankri, D., Cunningham, M. J. et al. · Nature (2024)
Tap, S. C. · Addiction Biology (2024)
Puigseslloses, P., Nadal-Gratacós, N., Ketsela, G. et al. · Molecular Psychiatry (2024)
Cameron, L. P., Benetatos, J., Lewis, V. et al. · Journal of Neuroscience (2023)
Jaster, A. M., González-Maeso, J. · Molecular Psychiatry (2023)
Heifets, B. D., Olson, D. E. · Neuropsychopharmacology (2023)